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Cancer-Related Fatigue in Adolescents
and Young Adults After Cancer Treatment:
Persistent and Poorly Managed
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Cancer-related fatigue is the most prevalent and distressing symptom experienced by adolescents and young
adults (AYAs). An electronic survey was undertaken to ascertain current fatigue management and perceptions
of its effectiveness. Eighty-five percent of responders (68/80) experienced fatigue, and it was worse more than
1 year after cancer treatment ended, compared to <1 year ( p= 0.007). Forty-one percent received no fatigue
management. Although advice to exercise was the most frequent intervention, the greatest impact of fatigue was
on the ability to exercise and most did not find exercise advice helpful. Early intervention is warranted,
supporting AYAs to persevere with increasing activity.
Keywords: fatigue, symptom control, quality of life, late effects
Introduction
Fatigue is one of the most prevalent, severe, and dis-tressing symptoms experienced by adolescents and
young adults (AYAs) with cancer.1,2 Healthy adolescents are
inherently susceptible to fatigue. The developmental changes
of adolescence mean that longer sleep times are needed,
while accompanying shifts in circadian rhythm result in later
bedtimes.3 Sleep is further hindered by use of light-producing
electronic devices in the bedroom, social commitments, and
alcohol consumption.3,4 AYA cancer patients experience
even more severe fatigue than their healthy counterparts.5–7
Young age and a cancer diagnosis, dual risk factors for fa-
tigue, combine to create a particularly significant problem in
this patient group.
Despite this, fatigue is a neglected symptom in AYAs, with
no interventional studies focusing on fatigue management at
this young age. Research evaluating interventions in older
adults has begun to accumulate over the last decade. The
most promising approaches are exercise and psychosocial
interventions such as education and treatment of concurrent
symptoms, with little evidence for pharmacological man-
agement.8–11 AYAs have unique needs that differ from those
of adults and children, and it is well recognized that research
outcomes in older adults cannot be extrapolated to the
younger population. This has led to an international drive to
develop evidence-based age-appropriate care.12,13
Preparatory research is needed to support the development
of an AYA fatigue intervention that meets their needs. Al-
though qualitative studies have provided insight into the un-
met needs of this young group,14–17 patients’ needs have not
been prioritized quantitatively, and there has been no evalu-
ation of the impact on carers.1 Furthermore, current practice
in fatigue management is unknown. The objectives of this
multicenter survey were to quantify the impact of fatigue on
young patients and their carers, to find out how fatigue is
currently being managed in the United Kingdom, and to as-
certain perceptions of the effectiveness of such management.
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Methods
Procedure
Participants were recruited from three Teenage and Young
Adult Principal Treatment Centres (TYA PTCs) in the United
Kingdom, and were required to have been diagnosed or
treated with cancer at age 13–24 and to be 16–27 at the time
of the survey.18
Electronic survey methods were used, following advice
from TYA PTC service users. After priming by email, poster,
and social media, a personalized email of invitation was sent
to potential participants, containing a unique token number
and links to the Participant Information Sheet and survey.
Nonresponders were ascertained by noting unused tokens,
and one reminder email was sent to nonresponders after
7 days. Approval was given by the National Research Ethics
Service Committee East of England—Cambridgeshire and
Hertfordshire (ref. 15/EE/0037).
Outcome measures
Demographic data were collected from both responders
and nonresponders. Participants completed two validated
measures. The PedsQL Multidimensional Fatigue Scale
(MFS) is a widely used 18-item scale validated in both ado-
lescents and in young adults; scores are linearly transformed
to a 0–100 scale, with lower scores representing worse fa-
tigue.19 The Quality of Life Visual Analog Scale (QOL-VAS)
is a single-item measure of quality of life that captures a
clinically significant change in quality of life more readily
than multiple-item measures.20,21
The severity of 11 symptoms and the impact of fatigue
were quantified using a 5-item verbal rating scale: ‘‘not at
all,’’ ‘‘a little bit,’’ ‘‘somewhat,’’ ‘‘quite a bit,’’ and ‘‘very
much.’’ The successfulness of each treatment received for
fatigue was rated using a 4-item scale: ‘‘entirely successful,’’
‘‘somewhat successful,’’ ‘‘helped only a little,’’ and ‘‘no ef-
fect.’’ A ‘‘successfulness score’’ for fatigue treatment was
generated by attributing 0, 1, 2, and 3 to the ratings ‘‘no
effect,’’ ‘‘helped only a little,’’ ‘‘somewhat successful,’’ and
‘‘entirely successful,’’ respectively, for each treatment re-
ceived and calculating a mean score. The former two ratings
defined an unsuccessful treatment and the latter two a suc-
cessful one. Selection of single ormultiple best responses was
used for a number of further questions, including defining the
two symptoms most affecting daily life, views on the cause of
the fatigue, and details of fatigue treatments received.
Participants indicating that fatigue had not affected them
over the past month only provided demographic information
and recorded the severity of the 11 symptoms, the 2 symp-
toms most affecting daily life, and the QOL-VAS. SPSS v22
was used for all analyses.
Results
The survey link was sent to 197 eligible patients and 80
responded, equating to a 41% response rate. Across all data
entry points, 1.8% were missing.
Characteristics of participants
There were two main differences between survey re-
sponders and nonresponders. First, no patients currently re-
ceiving cancer treatment participated. Second, significantly
more females than males responded, with 67% of responders
and 47% of nonresponders being female. However, after
excluding patients in the nonresponder group still receiving
treatment, to compare responders and nonresponders off
Table 1. Comparison of Responder and Nonresponder Demographic Data
Responders
(n = 80)
All
nonresponders
(n = 116) pa
Nonresponders
excluding those on
treatment (n= 93) pa
Off/on treatment,
n (missing data)
70/0 (10) 90/23 (3) <0.001b 90/0 (3) NA
Age at survey in years,
mean (SD, range)
22.1 (2.7, 17–27) 21.3 (2.7, 16–27) 0.06c 21.5 (2.6, 16–27) 0.21c
Age at diagnosis in years,
mean (SD, range)
18.9 (3.1, 12–24) 18.2 (3.3, 9–24) 0.12c 18.0 (3.2, 12–24) 0.06c
Months since diagnosis,
median (IQR)
31 (18–49) 31 (14–58) 0.85d 37 (21–61) 0.19d
Months since last treatment,
median (IQR)
18 (10–32) 18 (5–46) 0.50d 27 (11–52) 0.05d
Months treatment duration,
median (IQR)
8 (4–25) NA NA 6 (4–9) 0.006d
Gender, n, male (%) 26 (33) 62 (53) 0.005b 44 (47) 0.06b
Diagnosis, n (%)
Leukemia 20 (25) 20 (17) 0.44b 12 (13) 0.11b
Lymphoma 35 (44) 53 (46) 50 (54)
Osteosarcoma/Ewing’s 6 (8) 9 (8) 3 (3)
Brain neoplasm 1 (1) 8 (7) 6 (6)
Other 18 (23) 26 (22) 22 (24)
ap-Values comparing preceding column of nonresponders with responders and significant p-values in bold.
bFisher’s Exact Test.
cIndependent samples t-test.
dMann–Whitney U test.
IQR, interquartile range; SD, standard deviation.
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treatment, there was no longer evidence of a gender differ-
ence between the two groups (Table 1).
Impact of fatigue
Fatigue was the most prevalent symptom, experienced by
85% (68/80) during the precedingmonth (Fig. 1). Fatigue was
ranked as more severe than each of the other symptoms
(Wilcoxon signed-rank test; p < 0.001, except anxiety p =
0.007). The mean fatigue severity of the fatigued participants
was 44.3 (standard deviation [SD] 20.5). Fatigue severity was
worse more than 1 year after the last cancer treatment
(M= 39.0, SD = 19.7), compared to <1 year (M = 53.8,
SD = 19.7; independent samples t-test, t(56) = 2.8, p = 0.007).
Fatigue was worse in females (M = 39.6, SD = 19.3) than
males (M = 55.6, SD = 19.6; t(66) = 3.1, p = 0.003), but was
not associated with other demographic variables, including
cancer type or treatment duration. In a linear regression
analysis, anorexia and low mood explained 50% of the vari-
ation in fatigue severity (adjusted R2 0.50, F change = 26.60,
p < 0.001). Gender no longer had a statistically significant
relationship with fatigue after adjusting for anorexia and low
mood. Fatigue (MFS)was an independent predictor of quality
of life, after adjusting for the potential confounders, low
mood, and anorexia (adjusted R2 0.42, F change = 7.13,
p = 0.01).
All participants, including those not experiencing fatigue,
were asked which 2 out of 11 symptoms most affected daily
life. Fatigue was chosen more often than any other symptom
(Wilcoxon signed-rank tests, -7.87 < Z < -4.99, all p-values
<0.001). The greatest impact of fatigue on aspects of daily
life was on the ability to exercise, with 74% (50/68) experi-
encing ‘‘somewhat,’’ ‘‘quite a bit,’’ or ‘‘very much’’ impact.
Attending school or work was hindered for 65% and social-
izing for 56%. Forty-five percent of participants (29/64) felt
that their fatigue made the person most involved in their care
‘‘somewhat,’’ ‘‘quite a bit,’’ or ‘‘very much’’ upset, 42% (27/
64) felt it caused frustration, and 41% (26/64) believed it
limited rest time. Only 13% (8/64) thought that there was no
negative impact.
Fatigue management
A minority of fatigued participants (19%, 13/68) believed
that ‘‘something could be done’’ about fatigue, with many
(38%, 26/68) believing it to be a symptom one ‘‘has to live
with.’’ Although 65% (44/68) had talked to a health carer
about feeling fatigued; the most common reason for not
talking was a belief that nothing could be done (60%, 9/15).
Forty-one percent (28/68) of the fatigued participants had
not been recommended fatigue treatments. The remaining
participants had been recommended a median of 2.5 treat-
ments (range 1–7), most commonly advice to exercise (27/
40) or to rest and relax (22/40). There was no difference in
fatigue severity (MFS) between those recommended fatigue
treatments and those not. Only blood transfusion was per-
ceived as successful more often than unsuccessful (Fig. 2).
Successfulness of fatigue treatment was lower in participants
more than 1 year from last cancer treatment compared to
those <1 year from treatment [t(30) =-2.93, p = 0.006].
All participants, irrespective of whether they had received
fatigue treatment, were asked what they personally thought
was the single best treatment. Most chose exercise (24%, 14/
58), followed by diet/nutrition (12%, 7/58), rest/relaxation
(12%, 7/58), naps/sleeping (10%, 6/58), blood transfusion
(7%, 4/58), complementary therapies (5%, 3/58), physio-
therapy (3%, 2/58), and fatigue group attendance (3%, 2/58).
Thirteen of the 16 participants who recommended an active
treatment (exercise or physiotherapy) had received an ac-
tive treatment themselves; those who had received an active
treatment were more likely to recommend an active treatment
as being better than a rest-focused treatment (Fisher’s Exact
Test, p = 0.001). However, no evidence was found that those
who had received a rest-focused treatment (rest/relaxation,
naps/sleeping, or complementary therapy) were more likely
to recommend a rest-focused treatment ( p = 0.62).
FIG. 1. Symptom prevalence bar chart.
FIG. 2. Stacked bar chart showing successfulness of each
fatigue treatment.
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Discussion
This survey confirms that fatigue is the singlemost prevalent
and severe symptom experienced by AYAs with a cancer di-
agnosis and has the most negative impact on daily life. Fatigue
persisted long after the end of cancer treatment, being per-
ceived as worse more than 1 year after the end of treatment,
compared to during the first year following treatment.
Research to date has focused on the burden of fatigue
during cancer treatment. Only one study has shown worse
fatigue in AYA cancer survivors than controls,7 and there
have been no longitudinal studies evaluating fatigue changes
over time.1 One small, cross-sectional observational study
has evaluated fatigue according to the time after the end of
cancer treatment; there was a suggestion that fatigue in ad-
olescents more than 5 years after treatment (n = 8) could be
worse than those 1–2 years after treatment (n = 6).14
There may be a number of reasons for the persistence
of fatigue well beyond cancer treatment. Resting is coun-
terproductive as the inactivity caused by fatigue leads to a
destructive spiral of muscle deconditioning, loss of cardio-
respiratory fitness, and worsening fatigue.8,22 Furthermore,
AYA patients are at a formative age that puts them at par-
ticular risk of maladaptive behaviors such as activity avoid-
ance.23 Unhelpful health behaviors, such as inactivity, tend to
become lifelong habits, increasing the potential for long-term
disability. The finding that fatigue severity was worse more
than 1 year after the end of treatment may reflect this de-
conditioning spiral. It could also be that, further from the end
of treatment, the expectation that fatigue should be resolving
drives a perception of worse fatigue.
These data reveal concerning therapeutic nihilism and
under-management of fatigue. Over a decade ago, Stone et al.
undertook an influential multicenter survey of older adults with
cancer-related fatigue.24 While the proportion of people be-
lieving that ‘‘something could be done’’ about fatigue remained
comparably low (19% in this survey, 22% in Stone et al.), there
is evidence of progress. Sixty-five percent fatigued participants
in this survey had talked to a health carer about their fatigue;
59% had received some fatigue treatment and, of these, 68%
had received advice to exercise (respective figures in older
adults being 48%, 14%, and 4%).24 Exercise was viewed as the
best fatigue treatment and was most recommended to others.
The fact that most participants found exercise advice unhelpful
could be explained by the finding that fatigue has a particularly
negative impact on the ability to exercise.
The main limitation of this study is the risk of selection
bias. Although a nonresponder analysis was undertaken, fa-
tigue severitywas notmeasured in nonresponders. It is possible
that people experiencing fatigue may have been more likely to
participate, leading to fatigue overestimation. Greater selection
bias further from cancer treatment could have contributed to
the findings of worse fatigue and less successful fatigue man-
agement in those more than a year after cancer treatment. A
longitudinal cohort study, powered to detect changes in fatigue
over time, is needed to confirm the study findings.
Nevertheless, this study has a number of implications for
clinical practice. The persistence of fatigue, potentially sus-
tained by a spiral of inactivity and deconditioning, suggests
that early fatigue intervention is warranted, before mala-
daptive rest-based behaviors become entrenched at this for-
mative age. Given the impact of fatigue on the ability to
exercise, a fatigue intervention must find ways of engaging
AYAs in persisting with increasing activity, despite the
presence of fatigue. The negative consequences for carers
suggest that it would be beneficial to incorporate family
support into the intervention.
Considering the high prevalence and detrimental impact of
fatigue, it is concerning that there has as yet been no research
evaluating age-appropriate interventions. This survey provi-
des evidence for the specific needs of fatigued AYAs and is
supporting the design of future research aiming to develop
an effective treatment for this important and debilitating
symptom.
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